Shots:
The US FDA has granted Fast Track designation to Lu AH69593 for the treatment of patients with narcolepsy
Lu AH69593 is a small-molecule orexin 2 receptor agonist being developed by Lundbeck for narcolepsy to regulate arousal, wakefulness, & sleep-wake stability
Lu AH69593 is being evaluated in a P-Ib clinical program, with Lundbeck continuing to…
